A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia-Reference-Cited by-同舟云学术

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia

Published:2015-07 Issue:1 Volume:138 Page:55-61
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Hirte H.,Lheureux S.,Fleming G.F.,Sugimoto A.,Morgan R.,Biagi J.,Wang L.,McGill S.,Ivy S.P.,Oza A.M.

Funder

NCI-US-CTEP

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference37 articles.

1. Chemotherapy of advanced ovarian cancer;McGuire;Semin. Oncol.,1998

2. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer;Monk;Crit. Rev. Oncol. Hematol.,2013

3. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study;Burger;J. Clin. Oncol.,2007

4. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer;Cannistra;J. Clin. Oncol.,2007

5. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib;Gynecologic Oncology;2024-08

2. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer;Journal of Experimental & Clinical Cancer Research;2024-02-26

3. Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway;Frontiers in Oncology;2024-02-14

4. Diagnosis and treatment of ovarian cancer in the light of modern molecular genetic achievements;Siberian journal of oncology;2023-11-15

5. Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study;International Journal of Gynecologic Cancer;2023-09-29